Baird Medical Investment Holdings Ltd (BDMD) FinancialsBDMDBaird Medical Investment Holdings Ltd

Evaluating the bottom line, Baird Medical Investment Holdings Ltd maintains a gross margin of 83.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -113.73%, while the net margin is -122.20%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BDMD converts its operational activities into shareholder value.

In the context of the broader market, BDMD competes directly with industry leaders such as POCI and NEPH. With a market capitalization of $41.50M, it holds a significant position in the sector. When comparing efficiency, BDMD's gross margin of 83.79% stands against POCI's 23.61% and NEPH's 66.43%. Such benchmarking helps identify whether Baird Medical Investment Holdings Ltd is trading at a premium or discount relative to its financial performance.

Baird Medical's revenue for FY 2025 was $22.5 million, down from $32.7 million in 2024, reflecting a significant decline. The gross margin for 2025 was 83.8%, down from 88.2% in 2024, indicating pressure on profitability. The company also reported a GAAP EPS of -0.98 for FY 2025, highlighting ongoing financial struggles.